LINC01140 regulates osteosarcoma proliferation and invasion by targeting the miR-139-5p/HOXA9 axis

Shufang Zhang, Rongchun Chen *

The Spinal Surgery Department, People’s Hospital of Ganzhou City, Jiangxi Province, PR China

ARTICLE INFO

Keywords:
LINC01140  
Osteosarcoma  
mir-139-5p  
HOXA9  
EMT

ABSTRACT

Osteosarcoma is one of the commonest metastatic tumors in children and teenagers, and has a hopeless prognosis. Long non-coding RNA (lncRNA) acts as a regulator on the proliferation and migration of cancer. Here, we performed GEO database analysis and qPCR to identify differentially expressed lncRNAs in osteosarcoma cells. Knockdown of lncRNA LINC01140 was used to detect the effect of LINC01140 on the proliferation, invasion, and epithelial-mesenchymal transition (EMT) of osteosarcoma cells. Bioinformatics analysis and qPCR identified the LINC01140/miR-139-5p/Homeobox A9 (HOXA9) regulatory axis. RNA immunoprecipitation assay, Dual-luciferase assay, and rescue experiments confirmed the interaction of LINC01140/miR-139-5p/HOXA9 in osteosarcoma. LINC01140 was overexpressed in osteosarcoma and knocking down LINC01140 restrained the proliferation and invasion of osteosarcoma cells and EMT. In Saos2 and MG63 cells, LINC01140 sponged miR-139-5p, and a miR-139-5p inhibitor overturned the suppression of LINC01140 knockdown on the proliferation and migration of osteosarcoma cells. Moreover, miR-139-5p depressed the invasion, proliferation, and EMT of osteosarcoma cells via targeting HOXA9. Our results indicate that LINC01140 downregulation inhibits the invasion, proliferation, and EMT in osteosarcoma cells through targeting the miR-139-5p/HOXA9 axis. Therefore, LINC01140 is a potential therapeutic target for osteosarcoma.

1. Introduction

Osteosarcomas, one of the commonest primary malignant bone tumors that most commonly occur in children and teenagers are prone to invasion and distant metastasis [1]. The five-year survival rate of metastatic patients is extremely low [2]. Although in the past few decades, chemotherapy, surgery, radiotherapy, and targeted drugs have been used to remedy OS, the survival rate of metastatic patients has not ameliorated substantially [3]. Consequently, it is imperative to explore the molecular mechanism of OS growth and metastasis and identify novel therapeutic targets.

lncRNA is a subset of RNA that is not less than 200 nucleotides in length and does not encode protein [4]. lncRNAs can be used as a new type of potential tumor marker [5]. For example, MALAT1 and UCA1 can be used to detect early and metastatic lung cancer [6]. The expression of H19 and HOTAIR can be used as biomarkers for the detection of bladder cancer [7]. In addition, the differential expression of lncRNAs can promote or inhibit tumor growth and metastasis. Downregulating the expression of HOTAIR can reduce the occurrence and metastasis of breast cancer [8]. In summary, lncRNA-targeting cancer therapy is a promising field.

There are many mechanisms of action of lncRNA. In the cytoplasm, lncRNAs are mainly used as an endogenous competitive RNAs (ceRNAs) to sponge microRNAs and regulate the expression of messenger RNAs (mRNAs) [9]. TUG1 enhances the proliferation of OS cells via miR-132-5p/SOX4 axis [10]. LINC01140 can inhibit the proliferation and invasion of bladder cancer via regulating miR-140-5p to downregulate FGF9 expression. Moreover, LINC01140 is involved in poor prognosis of gastric cancer [11], nonetheless the function of LINC01140 in OS has not been reported.

To this end, here we studied the function of LINC01140 in osteosarcoma cells. Studies have found that inhibiting the expression of...
LINC01140 can effectively reduce the proliferation, invasion, and EMT of OS cells. Here, we also identified that LINC01140 regulates the expression of HOXA9 by combining with miR-139-5p to modulate the proliferation, invasion, and EMT of osteosarcoma. Therefore, LINC01140 is be a potential therapeutic target for osteosarcoma.

2. Materials and methods

Cell culture and transfaction. OS cell lines Saos2, MG63, normal osteoblasts cell line HFOB1.19 and 293 cell line were obtained from the American type culture collection (ATCC). These cells cultured in RPMI-1640 or DMEM (Gibco, Thermo) including 10% fetal bovine serum (FBS; American type culture collection (ATCC). These cells cultured in RPMI-1640 or DMEM (Gibco, Thermo) including 10% fetal bovine serum (FBS; American type culture collection (ATCC). The primer sequences used to analyze the expression of various RNAs and miRNAs. Table 2

Table 1
The sequence of siRNAs targeting LINC01140 and miR-139-5p mimics/inhibitor.

| Name                  | Sequence 5’-3’                                           |
|-----------------------|----------------------------------------------------------|
| siRNA-1               | CCACUAAUUCACAAUCUGAGU                                     |
| siRNA-2               | GAUUGGAUCUAAAAUUAUAU                                   |
| siRNA-3               | GAUCAUAUUAGUAUAUUUU                                    |
| si-con                | UUCUCGAGAGCAGCGAACU                                      |
| miR-139-5p mimics     | UCUAACUGUCAGCAGCU                                        |
| mimics nc             | UGGCAACUGUGCUGAACCU                                       |
| miR-139-5p inhibitor   | ACGGAGACAGUCUGACUGA                                      |
| inhibitor nc          | CAGCCUAUGUGAGAUAUAGG                                      |

RT-qPCR assay. Total RNA was extracted from Saos2 and MG63 cells with TRIZOL and determined with RNA electrophoresis in terms of purity and integrity. using random primers, total RNA was reverse-transcribed into cDNA (thermo). Target genes were amplified in 20 μL reaction volume and The operation steps follow the instructions of the SYBR Green qPCR Mix (Thermo Scientific). The sequences of the primers used for RT-qPCR analysis are listed in Table 2. The expression level of mRNA/IncRNA and miRNA was assessed using the 2^−ΔΔCt method [12].

Western blotting. 1 × 10^6 cells was lysed by the lysis buffer containing protease inhibitor cocktail. Denatured protein(20μg) is subjected to gel electrophoresis to separate the protein, and then the protein is transferred to the PVDF membrane (Millipore) and incubated with primary antibody at 4 °C overnight and the secondary antibody at RT for 1 h. Finally, the binding signal was visualized using the electro-chemiluminescence reagent (ECL, Thermo Scientific, Massachusetts, USA). Anti-GAPDH antibody was used as an internal reference (1:2000, 10494-1-AP, Proteintech). The antibody information is as follows: anti-HOXA9 (1:1000; ab140631, abcam), anti-Vimentin (1:1000; ab216347), and anti-Twist (1:100; ab50887, abcam), goat anti-rabbit anti-HOXA9 (1:1000; ab140631, abcam), anti-H19 (1:5000; SA00001-1, Proteintech), anti-LINC01296 (1:5000; SA00001-2, Proteintech), anti-MIR-145 (1:5000; SA00001-3, Proteintech), anti-NDRG2 (1:5000; SA00001-4, Proteintech), anti-MGAT4A (1:5000; SA00001-5, Proteintech), anti-TNIK (1:5000; SA00001-6, Proteintech), anti-PTPRD (1:5000; SA00001-7, Proteintech), anti-JAKMIP2 (1:5000; SA00001-8, Proteintech), anti-GAPDH antibody at 4 °C overnight and the secondary antibody at RT for 1 h. Finally, the binding signal was visualized using the electro-chemiluminescence reagent (ECL, Thermo Scientific, Massachusetts, USA). Anti-GAPDH antibody was used as an internal reference (1:2000, 10494-1-AP, Proteintech). The antibody information is as follows: anti-HOXA9 (1:1000; ab140631, abcam), anti-Vimentin (1:1000; ab216347), and anti-Twist (1:100; ab50887, abcam), goat anti-rabbit anti-HOXA9 (1:5000; SA00001-2, Proteintech) or goat anti-mouse antibody (1:5000; SA00001-3, Proteintech).

Cell Counting Kit-8 (CCK8) assay. Briefly, 3 × 10^3 cells/well were plated in 96-well plates. After 72 h, 10 μL CCK8 reagent (Solarbio) was added, and the cell viability was tested by measuring the optical density at 450 nm.
added into the wall including cells and incubated for 60 min. The level of proliferation was estimated at 490 nm using a microplate reader (51119670DP, Thermo Scientific).

Transwell migration and invasion assays. $5 \times 10^5$ cells transferred to the upper chamber of a Transwell plate containing culture medium (Serum free), and culture medium supplemented with 5% FBS was added into the lower chamber. After 48 h incubation, 4% paraformaldehyde was used to fix cells for 15 min, washed with PBS, and 0.1% crystal violet stained for 10 min. For the Transwell invasion assay, the experimental procedure was similar to the Transwell migration assay, and was performed using Transwell invasion plates.

Dual-luciferase assay. The HOXA9 3′UTR sequence (WT) and The HOXA9 3′UTR mutant sequence (MUT), or the LINC01140 sequence and the mutant sequence were synthesized and subcloned into the psiCHECK2 Vector (synbio-tech). Lipofectamine 2000 (Invitrogen) was used to co-transfect the luciferase reporter plasmid with miR-139-5p mimic or mimics nc in 293 cells. After 48 h, Firefly fluorescence value and Renilla fluorescence value were estimated using the dual-luciferase reporter assay (Promega). Relative fluorescence value is Renilla fluorescence value/Firefly fluorescence value, and the experiments were performed in three independent replicates.

RNA immunoprecipitation (RIP) assay. $1 \times 10^7$ cells were lysed with RIPA buffer (Beyotime, China) added protease inhibitor cocktail, take 10% Lysis mixture as Input, and incubate proteinA/G magnetic beads (millipore) coupled with anti-AGO2 antibody(ab186733, Abcam) and normal rabbit IgG (negative control) for 4 h. The magnetic beads of the coupled antibody were incubated with the lysis mixture for 6 h, and then the RNA was eluted and RT-qPCR was performed. Experiments were performed in three independent replicates.

Database analysis. RNA screening: The GSE28423 dataset contained data on OS cell lines, including four OS samples (GSM322697, GSM322698, GSM322699 GSM322700) and four human normal bone samples (GSM692388, GSM692389, GSM692390, GSM692391). We used the online tool GEO2R (ncbi.nlm.nih.gov/geo/geo2r) to recognize anomalously expressed lncRNA/mRNA that complyed with a standard of $p < 0.05$ and $\log_2|\text{FC}| > 2$. Volcano plot or Heatmap were drawn using the results of differentially expressed lncRNA/mRNAs. miRNA data were derived from dbDEMC (https://www.biosino.org/dbDEMC/index). The data from RNAinter (http://www.rna-society.org/rnainter/), TargetScan (http://www.targetscan.org/), and miRDB (http://www.mirdb.org/) were used to analyze potential genes interacting with miR-139-5p and LINC01140 or miR-139-5p and HOXA9.

Statistical analysis. All analysis data were analyzed by GraphPad Prism 8. The data are expressed as the mean ± standard deviation, and the two groups of data were analyzed by Student’s t-test, multiple groups were performed using one-way ANOVA followed by Bonferroni post-hoc test. $P < 0.05$ was considered to indicate a statistically significant difference.

3. Results

LncRNA LINC01140 is overexpressed in OS cells. The GEO database was screened to recognized the dissimilarly expressed lncRNAs in OS.
Among them, expression levels of 17 lncRNAs were elevated and those of 9 lncRNAs were repressed (Fig. 1A and B). The Fold change and p-values of these lists of lncRNAs are presented in Table 3.

We selected lncRNAs (LINC01140, LINC01296, H19, MEG3, MIR145) that differentially expressed Top5 for RT-qPCR detection, and the results showed that LINC01140 had the highest fold change of up-regulated expression in Saos2 and MG63 osteosarcoma cells, and MEG3 had the lowest fold change of down-regulated expression, compared with normal osteoblasts hFOB1.19 (Fig. 1C). A great deal of researches have validated that MEG3 is involved in the cell cycle, apoptosis, migration, and invasion of Saos2 and MG63 cells. Therefore, we inferred that MEG3 can be a promising target for the treatment of OS.

Table 3: The list of differentially expressed lncRNAs.

| Gene Symbol | Osteosarcoma Avg (log2) | Control Avg (log2) | Fold Change (log2) | P-val |
|-------------|-------------------------|-------------------|-------------------|-------|
| LINC01140   | 7.47                    | 4.74              | 6.6               | 0.015 |
| LINC01296   | 8.99                    | 6.43              | 5.91              | 2.76E-06 |
| H19         | 10.11                   | 7.94              | 4.48              | 3.4E-06 |
| DLEU2       | 9.47                    | 7.53              | 3.84              | 0.001 |
| GAS5        | 11.42                   | 9.77              | 3.13              | 7.15E-07 |
| TTLY1       | 6.14                    | 4.62              | 2.86              | 0.0089 |
| TUG1        | 11.46                   | 9.95              | 2.84              | 7.75E-06 |
| LINC01002   | 10.4                    | 8.95              | 2.74              | 0.0004 |
| LINC00537   | 8.62                    | 5.46              | 2.58              | 4.62E-05 |
| PPP1R3E     | 7.73                    | 6.44              | 2.44              | 2.92E-06 |
| LINC00839   | 7.86                    | 6.65              | 2.31              | 0.0004 |
| LINC01000   | 8.33                    | 7.16              | 2.26              | 3.54E-05 |
| GAS5        | 9.88                    | 8.72              | 2.23              | 0.0034 |
| LINC00174   | 6.79                    | 5.64              | 2.12              | 0.0002 |
| LINC00665   | 6.97                    | 5.84              | 2.19              | 0.0005 |
| LINC00852   | 7.89                    | 6.77              | 2.17              | 0.0001 |
| LINC01560   | 7.88                    | 6.87              | 2.03              | 0.0237 |
| DLEU1       | 6.92                    | 7.93              | -2.02             | 0.0003 |
| SNORD116-22 | 2.64                    | 3.74              | -2.14             | 0.0318 |
| MIR143      | 6.08                    | 7.53              | -2.73             | 6.32E-05 |
| LINC00670   | 4.81                    | 6.3               | -2.81             | 0.0158 |
| LINC00152   | 9.19                    | 11.2              | -4.01             | 8.17E-05 |
| LINC00998   | 6.96                    | 9.1               | -4.39             | 2.80E-05 |
| MIR145      | 5.66                    | 8.42              | -2.67             | 5.49E-06 |
| MEG3        | 6.6                     | 9.87              | -9.6              | 3.83E-08 |

(mir-139-5p) inhibits the proliferation and migration of OS cells by downregulating HOXA9 expression. Since miRNA can usually regulate the transcription and translation of downstream targets by binding to their 3' UTR region [15], we screened the mRNA interacting with mir-139-5p using the GEO database, targetscan, and miRDB database. The results showed that 65 mRNAs showed differential expression. Among them, expression levels of 34 mRNAs were upregulated, while those of 31 mRNAs were downregulated (Fig. 5A). Furthermore, we analysed the interaction between mir-139-5p and the TOP10 upregulated genes (Table 4) with RT-qPCR, compared with hFOB1.19 cells, RT-qPCR results exhibited that the expression of HOXA9 exhibited the highest degree of upregulation in Saos2 and MG63 cells (Fig. 5B). Therefore, we chose HOXA9 as a candidate target gene regulated by miR-139-5p. After mir-139-5p mimics were transfected into Saos2 and MG63 cells, and RT-qPCR and western blotting outcomes displayed that mir-139-5p constrained HOXA9 expression (Fig. 5C and D). Furthermore, the targetscan software predicted the binding region of mir-139-5p to the 3' UTR region of HOXA9 (Fig. 5E). To further validate that mir-139-5p regulates the proliferation and migration of OS cells, we co-transfected miR-139-5p mimics into Saos2 and MG63 cells, and RT-qPCR and western blotting outcomes displayed that mir-139-5p atrophic HOXA9 expression (Fig. 5F). To further validate that miR-139-5p regulates the proliferation and migration of OS cells, we co-transfected mir-139-5p mimics and ov-HOXA9 into Saos2 and MG63 cells. RT-qPCR results showed that HOXA9 was successfully overexpressed in mir-139-5p mimic transfected cells (Fig. 6A). Results of CCK8 and Transwell assays exhibited that the promotion of proliferation and migration in Saos2 and MG63 cells by mir-139-5p mimics could be inhibited by HOXA9 overexpression (Fig. 6B–D). Furthermore, Western blot outcomes exhibited that mir-139-5p mimics restrained the
Fig. 2. Knocking down LINC01140 expression in OS cell lines reduced their proliferation and migration, and epithelial-mesenchymal transition (EMT). (A, B) Relative expression of LINC01140 was evaluated by RT-qPCR after transfecting Saos2 and MG63 cells with siRNA targeting LINC01140. (C, D) CCK8 assay indicated LINC01140 knockdown reduced the proliferation in Saos2 and MG63 cells. (E, F) Transwell assay results revealed that the LINC01140 knockdown reduced the ability to migrate and invade in Saos2 and MG63 cells. (G) Western blot results showed that the LINC01140 knockdown inhibited the expression level of EMT-related Fibronectin, Vimentin, Snail, and Twist proteins. *P < 0.05. Abbreviations: CCK8, Cell Counting Kit-8; OS, osteosarcoma.
Fig. 3. LINC01140 acts as a sponge for miR-139-5p. (A, B) The subcellular localization of LINC01140 in Saos2 and MG63 cells was determined by RT-qPCR after extracting RNAs from cytoplasmic and nuclear extracts. C GAPDH and U6 were used as the cytoplasmic and nuclear RNA controls respectively. D Venn diagram representing the number of possible miRNAs sponged by LINC01140, identified as an overlapping area between transcripts downregulated in the dbDEMC dataset and RNAinter predicted LINC01140 target miRNAs. D RT-qPCR analysis analyzing the expression of the possible miRNAs sponged by LINC01140 in hFOB1.19, Saos2, and MG63 cells. E Heatmap of Differential expression profile in cancer vs normal tissues as derived from the dbDEMC dataset. F psiCHECK2-LINC01140-WT and psiCHECK2-LINC01140-WT or miR-139-5p mimics and mimics nc were transfected into 293T cells, dual luciferase reporter assay results showed that miR-139-5p could directly bind to LINC01140 and inhibit luciferase activity in 293T cells. G RT-qPCR results indicated that miR-139-5p did not impact the expression of LINC01140. (H, I) RIP assay results showed that miR-139-5p was associated with LINC01140 via the AGO2 protein in Saos2 and MG63 cells. *P < 0.05. RIP, RNA Binding Protein Immunoprecipitation Assay.
Fig. 4. miR-139-5p inhibitor restored the inhibitory effect of LINC01140 knockdown on the proliferation and migration of OS cells. (A, B) CCK8 assay indicated that miR-139-5p inhibitor increased the ability to proliferate in LINC01140-knocked down Saos2 and MG63 cells. (C, D) Transwell assay results revealed that miR-139-5p inhibitor increased the ability to migrate and invade in LINC01140-knocked down Saos2 and MG63 cells. *P < 0.05. Abbreviations: CCK8, Cell Counting Kit-8; OS, osteosarcoma.
expression of EMT-related proteins Fibronectin, Vimentin/snail/twist, and this downregulation could be reversed via the overexpression of EMT-related proteins Fibronectin, Vimentin/snail/twist, and HOXA9 (Fig. 6E). All in all, miR-139-5p restrained the proliferation, and this downregulation could be reversed via the overexpression of EMT-related proteins Fibronectin, Vimentin/snail/twist, and HOXA9 predicted by targetscan software and HOXA9 mutated sequence. F psiCHECK2-HOXA9-3′-UTR-WT and psiCHECK2-HOXA9-3′-UTR-MUT or miR-139-5p mimics and mimics nc were transfected into 293T cells, dual luciferase reporter assays showed that miR-139-5p could directly bind to the HOXA9 3′ UTR and inhibit luciferase activity in 293T cells. *P < 0.05. HOXA9, Abbreviations: Homeobox A9, WT, wild type; MUT, mutant.

4. Discussion

Osteosarcoma occurs in adolescents aged 15–19 years old, and the incidence is not high, but the disease develops rapidly and the mortality rate is high [1]. At present, the treatment methods for osteosarcoma include surgery, chemotherapy, targeted therapy, etc. Although these prolong the survival time of patients with osteosarcoma, their respective shortcomings, such as surgical therapy seriously reduces the quality of life of patients, chemotherapy drugs are prone to drug resistance and have low expression of miR-139-5p in serum is closely related to distal metastasis and poor prognosis in OS [30]. Moreover, miR-139-5p can inhibit the proliferation and invasion of OS, which is consistent with our findings. Furthermore, results of dual-luciferase and RIP assays confirmed the interaction between LINC01140 and miR-139-5p. Next, we integrated GEO sequencing data (GSE12865 and GSE27976), RT-qPCR results showed that LINC01140 is overexpressed in OS cells. This indicates that LINC01140 may contribute the occurrence and transfer of osteosarcoma. LncRNAs are participated in miscellaneous process of osteosarcoma development and distant metastasis, comprising proliferation, invasion, drug resistance, and EMT [22–24]. Here, we revealed that knocking down LINC01140 restrained OS proliferation and invasion as well as EMT. However, LINC01140 is reportedly related to poor prognosis in breast cancer [25]. We speculate that this difference in the expression and function of LINC01140 may be due to the tissue specificity of lncRNA. LncRNAs can be used as competing endogenous RNAs (ceRNAs) to influence the occurrence and development of tumors. By targeting miRNAs to regulate target genes, lncRNA SNHG3 regulates OS proliferation, invasion, and EMT of osteosarcoma through targeting HOXA9.

Table 4
Top 10 target genes with predicted upregulated expression.

| Gene symbol | Foldchange | P-value |
|-------------|------------|---------|
| PTPRD       | 18.01      | P < 0.05|
| TNK         | 6.96       | P < 0.05|
| RASGEF1B    | 6.21       | P < 0.05|
| MGAT4A      | 5.83       | P < 0.05|
| HOX9        | 5.8        | P < 0.05|
| NDRG2       | 4.62       | P < 0.05|
| ATP11A      | 4.38       | P < 0.05|
| HIPK1       | 4.3        | P < 0.05|
| HINBP1      | 3.74       | P < 0.05|
| JAKMIP2     | 3.63       | P < 0.05|

In recent years, lncRNAs have been confirmed to be anomalously expressed in various diseases, especially in cancer [5,17,18]. In addition, several investigations have demonstrated that a fraction of lncRNAs are differentially expressed in OS [19–21]. We screened the differentially expressed lncRNA, LINC01140, in osteosarcoma using the GEO database (GSE12865 and GSE27976). RT-qPCR results showed that LINC01140 is overexpressed in OS cells. This indicates that LINC01140 may contribute the occurrence and transfer of osteosarcoma. LncRNAs are participated in miscellaneous process of osteosarcoma development and distant metastasis, comprising proliferation, invasion, drug resistance, and EMT [22–24]. Here, we revealed that knocking down LINC01140 restrained OS proliferation and invasion as well as EMT. However, LINC01140 is reportedly related to poor prognosis in breast cancer [25]. We speculate that this difference in the expression and function of LINC01140 may be due to the tissue specificity of lncRNA.
Fig. 6. HOXA9 reversed the repressive effect of miR-139-5p on proliferation and invasion of OS cells. A RT-qPCR analysis of HOXA9 expression after transfection of miR-139-5p mimics or HOXA9 overexpression plasmid. B, C CCK8 assay indicated that HOXA9 reversed the repressive effect of miR-139-5p on proliferation of Saos2 and MG63 cells. D Transwell assay indicated that HOXA9 reversed the miR-139-5p mediated repression of migration and invasion in Saos2 and MG63 cells. E Western blot results indicated that HOXA9 reversed the inhibitory effects of miR-139-5p on the expression of the EMT-related protein, Fibronectin, Vimentin, Snail, and Twist, in Saos2 and MG63 cells. *P < 0.05. Abbreviations: Homeobox, WT, wild type; MUT, mutant; EMT, epithelial to mesenchymal transition.
HOXA9 expression was upregulated in Saso2 and MG63 cells, and it was validated to promote the proliferation, invasion, and EMT in OS. Our study does have some limitations. We did not clarify the mechanism on HOXA9 regulates the proliferation, invasion, and EMT in osteosarcoma. For instance, HOXA9 could be acted as a transcription factor to bind to the promoter region or enhancer region of downstream target genes to regulate the occurrence and metastasis of OS. This should be explored in the future studies.

In conclusion, our study outcomes show that the downregulation of LINC01140 can restrain the proliferation and invasion of OS through the miR-139-5p-HOXA9 axis. Therefore, LINC01140 is a potential therapeutic target for OS.

Ethics approval and consent to participate
Not applicable.

Funding
Not applicable.

Author contributions
SFZ conceived and designed the study and financed the research. SFZ and RCC performed the experiments. All authors read and approved the final manuscript.

Availability of data and materials
The datasets used and/or analyzed during the present study are available from the corresponding author on reasonable request.

Patient consent for publication
Not applicable.

Declaration of competing interest
All authors disclosed no relevant relationship.

Data availability
Data will be made available on request.

Acknowledgment
Not applicable.

References
[1] W. Zheng, Y. Huang, H. Chen, N. Wang, W. Xiao, Y. Liang, X. Jiang, W. Su, S. Wen, Nomogram application to predict overall and cancer-specific survival in osteosarcoma, Cancer Manag. Res. 10 (2018) 5439–5450, https://doi.org/10.2147/CMAR.S177945.
[2] L. Corre, F. Verrecchia, V. Creno, F. Redini, V. Trichet, The osteosarcoma microenvironment: a complex but targetable ecosystem, Cells 9 (2020), https://doi.org/10.3390/cells9040976.
[3] S. Tsukamoto, G. Errani, A. Angelini, A.F. Mavrogenis, Current treatment considerations for osteosarcoma metastatic at presentation, Orthopedics 43 (2020), e345, https://doi.org/10.3928/1944-2558-20200721-05 e358.
[4] T. Derrien, R. Johnson, G. Busstori, A. Tanzer, S. Djabali, H. Tilgner, G. Guerme, D. Martin, A. Merkel, D.G. Knowles, J. Lagarde, L. Veevavalli, X. Ruan, Y. Ruan, T. Lasman, P. Carinci, J.B. Brown, L. Lipovich, J.M. Gonzalez, M. Thomas, C. A. Davis, R. Shihekkattar, T.R. Girgeras, T.J. Hubbard, C. Notredame, J. Horrow, R. Guigo, The GENCODE v7 catalog of human long noncoding RNAs: analysis of their gene structure, evolution, and expression, Genome Res. 22 (2012) 1775–1789, https://doi.org/10.1101/gr.132159.111.
[5] A. Bhan, M. Soleimani, S.S. Mandal, Long noncoding RNA and cancer: a new paradigm, Cancer Res. 77 (2017) 3965–3981, https://doi.org/10.1158/0008-5472.CAN-16-3634.
[6] T. Gutschner, M. Hammerle, M. Eisemann, J. Hsu, Y. Kim, G. Hung, A. Revenko, G. Aram, M. Stentrup, M. Gross, M. Zornig, A.R. MacLeod, D.L. Spector, S. Diederichs, The noncoding RNA MALAT1 is a causal regulator of the metastasis phenotype of lung cancer cells, Cancer Res. 73 (2013) 1180–1189, https://doi.org/10.1158/0008-5472.CAN-12-2850.
[7] F. Wang, X. Li, X. Xie, L. Zhao, W. Chen, UCA1, a non-protein-coding RNA upregulated in bladder carcinoma and embryo, influencing cell growth and promoting invasion, FEBS Lett. 582 (2008) 1919–1927, https://doi.org/10.1016/j.jfle.2008.05.012.
[8] L. Zhang, X. Song, W. Xiang, W. Xie, Z. Wang, X. Yu, Z. Liang, H. Cao, Circulating DNA of HOTAIR in serum as a novel biomarker for breast cancer, Breast Cancer Res. Treat. 152 (2015) 199–208, https://doi.org/10.1007/s10549-015-3431-2.
[9] S. Sarthak, S. Subramanian, Competing endogenous RNAs (ceRNAs): new entrants to the intricacies of gene regulation, Front. Genet. 5 (2014) 8, https://doi.org/10.3389/fgene.2014.00008.
[10] S. Zhang and R. Chen
[11] [1] W. Zheng, Y. Huang, H. Chen, N. Wang, W. Xiao, Y. Liang, X. Jiang, W. Su, S. Wen, Nomogram application to predict overall and cancer-specific survival in osteosarcoma, Cancer Manag. Res. 10 (2018) 5439–5450, https://doi.org/10.2147/CMAR.S177945.
[2] L. Corre, F. Verrecchia, V. Creno, F. Redini, V. Trichet, The osteosarcoma microenvironment: a complex but targetable ecosystem, Cells 9 (2020), https://doi.org/10.3390/cells9040976.
[3] S. Tsukamoto, G. Errani, A. Angelini, A.F. Mavrogenis, Current treatment considerations for osteosarcoma metastatic at presentation, Orthopedics 43 (2020), e345, https://doi.org/10.3928/1944-2558-20200721-05 e358.
[4] T. Derrien, R. Johnson, G. Busstori, A. Tanzer, S. Djabali, H. Tilgner, G. Guerme, D. Martin, A. Merkel, D.G. Knowles, J. Lagarde, L. Veevavalli, X. Ruan, Y. Ruan, T. Lasman, P. Carinci, J.B. Brown, L. Lipovich, J.M. Gonzalez, M. Thomas, C. A. Davis, R. Shihekkattar, T.R. Girgeras, T.J. Hubbard, C. Notredame, J. Horrow, R. Guigo, The GENCODE v7 catalog of human long noncoding RNAs: analysis of their gene structure, evolution, and expression, Genome Res. 22 (2012) 1775–1789, https://doi.org/10.1101/gr.132159.111.
[5] A. Bhan, M. Soleimani, S.S. Mandal, Long noncoding RNA and cancer: a new paradigm, Cancer Res. 77 (2017) 3965–3981, https://doi.org/10.1158/0008-5472.CAN-16-3634.
[29] J.H. Zhu, R.A. De Mello, Q.L. Yan, J.W. Wang, Y. Chen, Q.H. Ye, Z.J. Wang, H. J. Tang, T. Huang, MiR-139-5p/SLC7A11 inhibits the proliferation, invasion and metastasis of pancreatic carcinoma via PI3K/Akt signaling pathway, Biochim. Biophys. Acta, Mol. Basis Dis. 1866 (2020), 165747, https://doi.org/10.1016/j.bbmb.2020.165747.

[30] Y.K. Shi, Y.H. Guo, MiR-139-5p suppresses osteosarcoma cell growth and invasion through regulating DNMT1, Biochem. Biophys. Res. Commun. 503 (2018) 459–466, https://doi.org/10.1016/j.bbrc.2018.04.124.

[31] K. Qin, G. Tian, G. Chen, D. Zhou, K. Tang, miR-647 inhibits glioma cell proliferation, colony formation and invasion by regulating HOXA9, J. Gene Med. 22 (2020) e3153, https://doi.org/10.1002/jgm.3153.

[32] Q. Xu, Q. Zhang, M. Dong, Y. Yu, MicroRNA-638 inhibits the progression of breast cancer through targeting HOXA9 and suppressing Wnt/beta-cadherin pathway, World J. Surg. Oncol. 19 (2021) 247, https://doi.org/10.1186/s12957-021-02503-7.

[33] Z. Fu, C. Chen, Q. Zhou, Y. Wang, Y. Zhao, X. Zhao, W. Li, S. Zheng, H. Ye, L. Wang, Z. He, Q. Lin, Z. Li, R. Chen, LncRNA HOTTIP modulates cancer stem cell properties in human pancreatic cancer by regulating HOXA9, Cancer Lett. 410 (2017) 68–81, https://doi.org/10.1016/j.canlet.2017.09.019.